CN103920066A - Method for preparing medicament for treating acute gouty arthritis - Google Patents
Method for preparing medicament for treating acute gouty arthritis Download PDFInfo
- Publication number
- CN103920066A CN103920066A CN201410180161.3A CN201410180161A CN103920066A CN 103920066 A CN103920066 A CN 103920066A CN 201410180161 A CN201410180161 A CN 201410180161A CN 103920066 A CN103920066 A CN 103920066A
- Authority
- CN
- China
- Prior art keywords
- parts
- herba
- radix
- filtrate
- semen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention relates to a method for preparing a medicament for treating acute gouty arthritis. The method comprises the following steps: (1) adding 3 liters of water into raw medicinal materials, refluxing for 6 hours at 100 DEG C, and filtering to obtain filtrate 1 and filter residue 1; (2) adding 2 liters of water into the filter residue 1, refluxing for 5 hours at 90 DEG C, and filtering to obtain filtrate 2 and filter residue 2; (3) adding 2 liters of water into the filter residue 2, refluxing for 3 hours at 90 DEG C, and filtering to obtain filtrate 3 and filter residue 3; and (4) combining the filtrate 1, the filtrate 2 and the filtrate 3, concentrating to 2,000 millimeters, and cooling to room temperature. The medicament prepared by the method is reasonable in formula, has the characteristics of exact curative effect, no toxic or side effect and low price, and is safe and convenient.
Description
Technical field
The present invention relates to field of medicaments, relate in particular to a kind of medicine for the treatment of acute gouty arthritis.
Background technology
Gout is due to a kind of disease due to purine metabolic disturbance, and its clinical characters is hyperuricemia and the arthritis of outbreak repeatedly.Acute gouty arthritis onset is anxious, many night-time attacks, red taking joint, swollen, hot, bitterly and limitation of activity be main manifestations, belong to Chinese medicine " pyretic arthralgia " category.In recent years, along with the raising day by day of living standard and the change of dietary structure, the sickness rate of gouty arthritis obviously rises, its main patient is middle-aging male, being more than 40 years old modal a kind of arthritis in male, and having the trend of rejuvenation gradually, is one of clinical difficult treatment.
Summary of the invention
The object of this invention is to provide a kind of preparation method of medicine for the treatment of acute gouty arthritis.
In order to realize object of the present invention, the invention provides a kind of preparation method of medicine for the treatment of acute gouty arthritis, the method comprises the following steps:
1) in crude drug, add 3 premium on currency, reflux 6 hours at 100 DEG C, filters, and obtains filtrate 1 and filtering residue 1;
2) in described filtering residue 1, add 2 premium on currency, reflux 5 hours at 90 DEG C, filters, and obtains filtrate 2 and filtering residue 2;
3) in described filtering residue 2, add 2 premium on currency, reflux 3 hours at 90 DEG C, filters, and obtains filtrate 3 and filtering residue 3; And
4) merge described filtrate 1, filtrate 2 and filtrate 3, be concentrated into 2000 milliliters, be cooled to room temperature.
Preferably, the medical material that described crude drug comprises following weight portion: Herba Epimedii 1-10 part, Radix Codonopsis 10-30 part, Rhizoma Atractylodis 1-10 part, Dali chrysanthemum 1-20 part, Cortex Magnoliae Officinalis 1-10 part, Rhizoma Dioscoreae 10-30 part, Radix Salviae Miltiorrhizae 1-10 part, Poria 10-30 part, Radix Ampelopsis Cantoniensis 10-30 part, Semen Coicis 10-30 part, Fructus Corni 10-30 part, Semen Lablab Album 10-30 part, Radix Morindae Officinalis 1-10 part and Radix Achyranthis Bidentatae 1-20 part.
Preferably, the medical material that described crude drug comprises following weight portion: 10 parts of 6 parts of Herba Epimedii, 15 parts of Radix Codonopsis, 6 parts of Rhizoma Atractylodis, 10 parts of Dali chrysanthemums, 8 parts of Cortex Magnoliae Officinalis, 20 parts of Rhizoma Dioscoreaes, 8 parts of Radix Salviae Miltiorrhizaes, 18 parts, Poria, 20 parts of Radix Ampelopsis Cantoniensiss, 13 parts of Semen Coiciss, 12 parts of Fructus Corni, 12 parts of Semen Lablab Albums, 7 parts of Radix Morindae Officinaliss and Radix Achyranthis Bidentataes.
Preferably, described crude drug also comprises the medical material of following weight portion: Herba Asari 10-20 part, Caulis Spatholobi 1-10 part, Herba Ipomoeae Cairicae 10-30 part, Caulis Lonicerae 10-30 part, Radix Arnebiae (Radix Lithospermi) 10-20 part, Herba Gerberae Piloselloidis 1-20 part, Semen Persicae 1-20 part, Herba Epilobii Pyrricholophi 1-20 part, Rhizoma Curculiginis 10-20 part, Herba Selaginellae Doederleinii 10-30 part, Fructus Chaenomelis 1-10 part, Radix Rhodiolae 1-10 part, the sub-10-30 part of Folium Bambusae, Semen Vaccariae 1-10 part, Scolopendra 1-10 part, Scorpio 1-10 part, Herba Farfugii japonici 10-30 part, Fructus Rosae Laevigatae 1-10 part, Cortex Cinnamomi 10-20 part, Cortex Fraxini 1-10 part and Herba Taraxaci 1-10 part.
Preferably, described crude drug also comprises the medical material of following weight portion: 9 parts of 12 parts of Herba Asaris, 9 parts of Caulis Spatholobis, 20 parts of Herba Ipomoeae Cairicaes, 11 parts of Caulis Loniceraes, 12 parts of Radix Arnebiae (Radix Lithospermi)s, 10 parts of Herba Gerberae Piloselloidiss, 10 parts, Semen Persicae, 10 parts of Herba Epilobii Pyrricholophi, 13 parts of Rhizoma Curculiginises, 15 parts of Herba Selaginellae Doederleiniis, 6 parts of Fructus Chaenomeliss, 8 parts of Radix Rhodiolaes, 20 parts of Folium Bambusae, 5 parts of Semen Vaccariae, 6 parts of Scolopendras, 3 parts of Scorpios, 15 parts of Herba Farfugii japonicis, 8 parts of Fructus Rosae Laevigatae, 14 parts of Cortex Cinnamomis, 8 parts of Cortex Fraxinis and Herba Taraxacis.
In the present invention:
Dali chrysanthemum
Base is former: the tuber of Compositae dahlia plant Dahlia Pinnata Cav.
Dahlia?pinnata?Cav.[D.uariabilis?Desf.]
Radix Ampelopsis Cantoniensis
Base is former: root or the Herb of Vitaceae Caulis seu folium ampelopsis brevipedunculatae (Caulis Ampelopsis Brevipedunculae) Serpentis platymiscium Caulis seu folium ampelopsis brevipedunculatae in Guangdong
Former plant: Caulis seu folium ampelopsis brevipedunculatae in Guangdong Ampelopsis cantoniensis (Hook.et Arn.) Planch.[Cissus cantosniensis Hook.et Arn.]
Herba Ipomoeae Cairicae
Base is former: root or the branch of Moraceae fig ficus simplicissima.
Former plant: ficus simplicissima Ficus hirta Vahl[F.simplicissima Lour.var.hira (Vahl) Migo]
Herba Epilobii Pyrricholophi
Base is former: the Herb of the long seed LIUYECAI of onagraceae plant
Former plant: long seed LIUYECAI Epilobium pyrricholophum Franch.et Sav.
Herba Farfugii japonici
Base is former: the herb of feverfew Farfugium japonicum
Former plant: Farfugium japonicum Farfugium japonicum (L.) Kitam.
For compositions of the present invention, according to the prescription compatibility theory of " monarch, minister, help, make ", Dali chrysanthemum, Herba Epilobii Pyrricholophi, Folium Bambusae are monarch drug; Herba Epimedii, Fructus Corni, Caulis Lonicerae, Semen Lablab Album, Herba Selaginellae Doederleinii, Caulis Spatholobi, Cortex Cinnamomi, Semen Coicis, Radix Morindae Officinalis, Radix Achyranthis Bidentatae, Semen Persicae are ministerial drug; Radix Codonopsis, Rhizoma Atractylodis, Radix Ampelopsis Cantoniensis, Rhizoma Curculiginis, Fructus Chaenomelis, Herba Farfugii japonici, Radix Arnebiae (Radix Lithospermi), Radix Rhodiolae, Semen Vaccariae, Poria, Rhizoma Dioscoreae, Herba Asari, Fructus Rosae Laevigatae, Radix Salviae Miltiorrhizae, Cortex Magnoliae Officinalis, Herba Taraxaci are adjuvant drug; Herba Ipomoeae Cairicae, Herba Gerberae Piloselloidis, Scolopendra, Scorpio and Cortex Fraxini are for making medicine.All medicines are harmonious in the present invention, and reasonable recipe has determined curative effect, safe ready, has no side effect, cheap feature.
Detailed description of the invention
Further illustrate the present invention below by embodiment.It should be understood that embodiments of the invention are for the present invention instead of limitation of the present invention are described.The simple modifications that essence according to the present invention is carried out the present invention all belongs to the scope of protection of present invention.Except as otherwise noted, the percent otherwise in the present invention is percetage by weight.
Embodiment lotion of the present invention
Take 6 grams of Herba Epimedii, 15 grams of Radix Codonopsis, 6 grams of Rhizoma Atractylodis, 10 grams of Dali chrysanthemums, 8 grams of Cortex Magnoliae Officinalis, 20 grams of Rhizoma Dioscoreaes, 8 grams of Radix Salviae Miltiorrhizaes, 18 grams, Poria, 20 grams of Radix Ampelopsis Cantoniensiss, 13 grams of Semen Coiciss, 12 grams of Fructus Corni, 12 grams of Semen Lablab Albums, 7 grams of Radix Morindae Officinaliss, 10 grams of Radix Achyranthis Bidentataes, 12 grams of Herba Asaris, 9 grams of Caulis Spatholobis, 20 grams of Herba Ipomoeae Cairicaes, 11 grams of Caulis Loniceraes, 12 grams of Radix Arnebiae (Radix Lithospermi)s, 10 grams of Herba Gerberae Piloselloidiss, 10 grams, Semen Persicae, 10 grams of Herba Epilobii Pyrricholophi, 13 grams of Rhizoma Curculiginises, 15 grams of Herba Selaginellae Doederleiniis, 6 grams of Fructus Chaenomeliss, 8 grams of Radix Rhodiolaes, 20 grams of Folium Bambusae, 5 grams of Semen Vaccariae, 6 grams of Scolopendras, 3 grams of Scorpios, 15 grams of Herba Farfugii japonicis, 8 grams of Fructus Rosae Laevigatae, 14 grams of Cortex Cinnamomis, 9 grams of 8 grams of Cortex Fraxinis and Herba Taraxacis, add 3 premium on currency, reflux 6 hours at 100 DEG C, filter, obtain filtrate 1 and filtering residue 1, 2) in described filtering residue 1, add 2 premium on currency, reflux 5 hours at 90 DEG C, filters, and obtains filtrate 2 and filtering residue 2, 3) in described filtering residue 2, add 2 premium on currency, reflux 3 hours at 90 DEG C, filters, and obtains filtrate 3 and filtering residue 3, and 4) merge described filtrate 1, filtrate 2 and filtrate 3, be concentrated into 2000 milliliters, be cooled to room temperature.
Experimental example
Physical data
Be collected in the 48 routine patients that in January, 2013 to 2013, year December was gone to a doctor to my institute, be divided into two groups.Treatment group 24 examples, male 12 examples, female's 12 examples; Age 22-71 year, average (41.6 ± 10.2) year; Course of disease 1d-3, average (2.8 ± 1.9) year; Invade the first metatarsophalangeal joints 19 examples, ankle joint 3 examples, carpal joint 1 example, knee joint 1 example (wherein 2 examples are multi-joint).Matched group 24 examples, male 12 examples, female's 12 examples; Age 23-70 year, average (41.2 ± 10.5) year; Course of disease 1d-3, average (2.6 ± 1.8) year; Invade the first metatarsophalangeal joints 20 examples, ankle joint 2 examples, carpal joint 1 example, knee joint 1 example.Sex, age, the course of disease of two groups learned processing (t inspection) by statistics, and the equal not statistically significant of difference (P>0.05), has comparability.
Diagnostic criteria
With reference to (Meng Zhao enjoys. gout [M]. and Beijing: Beijing Medical University. combined publication society of China Concord Medical Science University, 1997; 120-121,131.) formulate following diagnostic criteria: 1. there is the outbreak of more than 1 time acute arthritis; 2. inflammation peaks within 1d; 3. monarthritis outbreak; 4. arthremia swelling; 5. the first metatarsophalangeal joints pain or swelling; 6. one-sided the first metatarsophalangeal joints outbreak of swelling and ache; 7. involve one-sided midtarsal joints; 8. suspicious tophus; 9. serum uric acid level raises; 10. an asymmetric arthralgia, x-ray shows that under cortical bone, cystis degeneration does not accompany bone to infiltrate, between arthritis stage of attack, joint fluid antibacterial culturing feminine gender.Having more than 6 person in above 10 can make a definite diagnosis, or has following 3 persons and also can make a definite diagnosis: 1. typical monarthritis has 1 asymptomatic intermission thereupon; 2. give after Effects of Colchicine In Treating, synovitis can be alleviated rapidly, has special treatment effect; 3. hyperuricemia.
Exclusion standard
1. merge cardiovascular and cerebrovascular vessel, Liver and kidney and hemopoietic system and serious primary disease person.2. late period joint severe deformity, stiff, disability person.
Treatment group is used the lotion of preparing in embodiment, in the time for the treatment of, gets 100 milliliters of lotions, with gauze adhesional wetting, till wiping painful area to skin indistinctly generates heat repeatedly.Treat every day 2 times.Matched group is taken XINHUANGPIAN, the Xiamen pharmaceutical factory of traditional Chinese medicine produce, boiled water is taken after mixing it with water, one time 3, every day 2 times.During two groups of patient treatments, all keep on a diet, the food of purine and nucleic acid etc. is rich in requirement alcohol prohibition, fasting, drinks more water, and urinates more.
Curative effect determinate standard
1. effective: arthralgia swelling disappears, movable normal; Effective: arthralgia, swelling alleviate, movable function takes a turn for the better; Invalid: arthralgia, swelling is without improvement, movable function obstacle.2. the arthralgia relief time.Medication starts the time painless to joint.
Adopt SPSS12.0 software data processing, carry out t inspection and x
2inspection.
Result
The therapeutic effect of two groups sees the following form 1.
| Group | Number of cases | Effective | Effectively | Invalid | Total effective rate |
| Matched group | 24 | 17 | 4 | 3 | 87.5％ |
| Treatment group | 24 | 22 | 2 | 0 | 100％ a |
Note: with matched group comparison,
ap<0.05
Two groups of arthralgia relief time and swelling regression time relatively see the following form 2.
Table 2 liang group arthralgia relief time and the comparison of swelling regression time
Note: with matched group comparison,
ap < 0.05.
Claims (5)
1. a preparation method for the treatment of the medicine of acute gouty arthritis, is characterized in that, the method comprises the following steps:
1) in crude drug, add 3 premium on currency, reflux 6 hours at 100 DEG C, filters, and obtains filtrate 1 and filtering residue 1;
2) in described filtering residue 1, add 2 premium on currency, reflux 5 hours at 90 DEG C, filters, and obtains filtrate 2 and filtering residue 2;
3) in described filtering residue 2, add 2 premium on currency, reflux 3 hours at 90 DEG C, filters, and obtains filtrate 3 and filtering residue 3; And
4) merge described filtrate 1, filtrate 2 and filtrate 3, be concentrated into 2000 milliliters, be cooled to room temperature.
2. preparation method according to claim 1, it is characterized in that the medical material that described crude drug comprises following weight portion: Herba Epimedii 1-10 part, Radix Codonopsis 10-30 part, Rhizoma Atractylodis 1-10 part, Dali chrysanthemum 1-20 part, Cortex Magnoliae Officinalis 1-10 part, Rhizoma Dioscoreae 10-30 part, Radix Salviae Miltiorrhizae 1-10 part, Poria 10-30 part, Radix Ampelopsis Cantoniensis 10-30 part, Semen Coicis 10-30 part, Fructus Corni 10-30 part, Semen Lablab Album 10-30 part, Radix Morindae Officinalis 1-10 part and Radix Achyranthis Bidentatae 1-20 part.
3. preparation method according to claim 2, it is characterized in that the medical material that described crude drug comprises following weight portion: 10 parts of 6 parts of Herba Epimedii, 15 parts of Radix Codonopsis, 6 parts of Rhizoma Atractylodis, 10 parts of Dali chrysanthemums, 8 parts of Cortex Magnoliae Officinalis, 20 parts of Rhizoma Dioscoreaes, 8 parts of Radix Salviae Miltiorrhizaes, 18 parts, Poria, 20 parts of Radix Ampelopsis Cantoniensiss, 13 parts of Semen Coiciss, 12 parts of Fructus Corni, 12 parts of Semen Lablab Albums, 7 parts of Radix Morindae Officinaliss and Radix Achyranthis Bidentataes.
4. preparation method according to claim 3, it is characterized in that, described crude drug also comprises the medical material of following weight portion: Herba Asari 10-20 part, Caulis Spatholobi 1-10 part, Herba Ipomoeae Cairicae 10-30 part, Caulis Lonicerae 10-30 part, Radix Arnebiae (Radix Lithospermi) 10-20 part, Herba Gerberae Piloselloidis 1-20 part, Semen Persicae 1-20 part, Herba Epilobii Pyrricholophi 1-20 part, Rhizoma Curculiginis 10-20 part, Herba Selaginellae Doederleinii 10-30 part, Fructus Chaenomelis 1-10 part, Radix Rhodiolae 1-10 part, the sub-10-30 part of Folium Bambusae, Semen Vaccariae 1-10 part, Scolopendra 1-10 part, Scorpio 1-10 part, Herba Farfugii japonici 10-30 part, Fructus Rosae Laevigatae 1-10 part, Cortex Cinnamomi 10-20 part, Cortex Fraxini 1-10 part and Herba Taraxaci 1-10 part.
5. preparation method according to claim 4, it is characterized in that, described crude drug also comprises the medical material of following weight portion: 9 parts of 12 parts of Herba Asaris, 9 parts of Caulis Spatholobis, 20 parts of Herba Ipomoeae Cairicaes, 11 parts of Caulis Loniceraes, 12 parts of Radix Arnebiae (Radix Lithospermi)s, 10 parts of Herba Gerberae Piloselloidiss, 10 parts, Semen Persicae, 10 parts of Herba Epilobii Pyrricholophi, 13 parts of Rhizoma Curculiginises, 15 parts of Herba Selaginellae Doederleiniis, 6 parts of Fructus Chaenomeliss, 8 parts of Radix Rhodiolaes, 20 parts of Folium Bambusae, 5 parts of Semen Vaccariae, 6 parts of Scolopendras, 3 parts of Scorpios, 15 parts of Herba Farfugii japonicis, 8 parts of Fructus Rosae Laevigatae, 14 parts of Cortex Cinnamomis, 8 parts of Cortex Fraxinis and Herba Taraxacis.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410180161.3A CN103920066B (en) | 2014-04-30 | 2014-04-30 | A kind of preparation method for the treatment of the medicine of acute gouty arthritis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410180161.3A CN103920066B (en) | 2014-04-30 | 2014-04-30 | A kind of preparation method for the treatment of the medicine of acute gouty arthritis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103920066A true CN103920066A (en) | 2014-07-16 |
| CN103920066B CN103920066B (en) | 2016-03-30 |
Family
ID=51138608
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410180161.3A Expired - Fee Related CN103920066B (en) | 2014-04-30 | 2014-04-30 | A kind of preparation method for the treatment of the medicine of acute gouty arthritis |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103920066B (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109820974A (en) * | 2019-03-27 | 2019-05-31 | 苏凤哲 | A kind of Chinese medicine composition and its preparation method and application for treating hyperuricemia |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101152408A (en) * | 2007-09-24 | 2008-04-02 | 天津大学 | Pharmaceutical composition having function cancer of the lungs against |
| CN101190294A (en) * | 2006-11-23 | 2008-06-04 | 肖凡 | Traditional Chinese medicine for treating gout disease |
| CN101199779A (en) * | 2007-12-21 | 2008-06-18 | 北京中科雍和医药技术有限公司 | Medicament compound for treating acute gout arthritis and preparing method thereof |
| CN101264215A (en) * | 2008-04-25 | 2008-09-17 | 北京中泰天和科技有限公司 | Medicinal composition for treating acute and chronic urarthritis and preparation thereof |
-
2014
- 2014-04-30 CN CN201410180161.3A patent/CN103920066B/en not_active Expired - Fee Related
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101190294A (en) * | 2006-11-23 | 2008-06-04 | 肖凡 | Traditional Chinese medicine for treating gout disease |
| CN101152408A (en) * | 2007-09-24 | 2008-04-02 | 天津大学 | Pharmaceutical composition having function cancer of the lungs against |
| CN101199779A (en) * | 2007-12-21 | 2008-06-18 | 北京中科雍和医药技术有限公司 | Medicament compound for treating acute gout arthritis and preparing method thereof |
| CN101264215A (en) * | 2008-04-25 | 2008-09-17 | 北京中泰天和科技有限公司 | Medicinal composition for treating acute and chronic urarthritis and preparation thereof |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109820974A (en) * | 2019-03-27 | 2019-05-31 | 苏凤哲 | A kind of Chinese medicine composition and its preparation method and application for treating hyperuricemia |
Also Published As
| Publication number | Publication date |
|---|---|
| CN103920066B (en) | 2016-03-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103446567B (en) | Premenstrual ease pharmaceutical composition and preparation technique thereof | |
| CN103432534B (en) | Traditional Chinese prescription for treating hyperplasia of mammary glands | |
| CN100444889C (en) | Chinese medicinal composition for treating mastopathy | |
| CN101983689B (en) | Drug for treating prostatitis and preparation method thereof | |
| CN101804189B (en) | Drug for treating primary dysmenorrhea | |
| CN101618152A (en) | Jingfang Yinqiao health tea for old people | |
| CN103920066B (en) | A kind of preparation method for the treatment of the medicine of acute gouty arthritis | |
| CN103893601B (en) | A kind of medicament for the treatment of mumps | |
| CN103705846A (en) | Traditional Chinese medicine preparation for treating ovarian cyst | |
| CN105213972A (en) | A kind of pharmaceutical preparation of promoting blood circulation to remove obstruction in the collateral and application thereof | |
| CN105213973A (en) | For alleviating the pharmaceutical composition of symptom before feminine menstrual | |
| CN104367788A (en) | Pharmaceutical composition compounded with marine organism polysaccharide as well as preparation method and application of pharmaceutical composition | |
| CN102671179A (en) | Traditional Chinese medicine for treating post-abortion metrorrhagia and preparation method thereof | |
| CN103301368A (en) | Medicament for treating hyperactivity | |
| CN103705840A (en) | Medicinal composition for treating acute and chronic cholecystitis, and cholelithiasis, and preparation method thereof | |
| CN102228661B (en) | Chinese medicinal cholecystitis treatment mixture for treating chronic cholecystitis | |
| CN102743652B (en) | Chinese medicinal preparation for treating male infertility | |
| CN105343741A (en) | Traditional Chinese medicine for treating thyroid tumor and preparation method of traditional Chinese medicine | |
| CN106138618B (en) | A pharmaceutical composition for treating angina pectoris, and its preparation method | |
| CN104758346A (en) | Medicine for treating migraine, as well as preparation method and preparation of medicine | |
| CN104740579A (en) | Premenstrual calming tablet and preparation process thereof | |
| CN104288582B (en) | A kind of Chinese medicine composition for treating oedema | |
| CN104491523A (en) | Medicament for treating chronic cholecystitis | |
| CN104147352A (en) | Traditional Chinese medicinal preparation for treating protrusion of lumbar intervertebral disc | |
| CN115887590A (en) | Mongolian medicine medicated bath composition for treating psoriasis as well as preparation method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20160330 Termination date: 20170430 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |